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Lewy body diseases (LBDs) are a heterogeneous group 
of disorders that include Parkinson’s disease (PD), PD 
with dementia (PDD) and dementia with Lewy bod‑
ies (DLB)1. Together, these diseases affect over 5 mil‑
lion people worldwide. LBDs are mainly characterized 
pathologically by the progressive accumulation of the 
presynaptic protein α‑synuclein (α‑syn) — hence they 
are often referred to as synucleinopathies — and by the 
degeneration of neocortical, limbic and nigral‑striato 
circuitries2,3. A pathogenic role for α‑syn in these disor‑
ders is supported by various genetic data. Multiplications 
of the gene encoding α‑syn (SNCA)4 and various point 
mutations in this gene (A53T, A30P and E46K)5–7 result 
in dominant familial parkinsonism. Moreover, certain 
polymorphisms in SNCA are major risk factors for 
sporadic PD8.
An increasing body of evidence from animal models 
as well as data from genetic, biochemical and biophysi‑
cal studies support the hypothesis that the processes 
of α‑syn oligomerization9,10 and fibril growth11,12 have 
central roles in the pathogenesis of PD and other synu‑
cleinopathies13. In addition, it is possible that the α‑syn 
monomers might also have a role in synucleinopathies 
by their displacement from their physiological location, 
resulting in a loss of cellular function, or by disrupting 
the activity of other molecular or signalling pathways14. 
Nevertheless, the molecular mechanisms by which 
α‑syn aggregation contributes to neurodegeneration, 
the nature of the toxic forms of α‑syn and the cellular 
pathways that are affected by α‑syn remain unknown. 
Addressing these knowledge gaps will be crucial for 
understanding the molecular basis of synucleinopathies, 
developing tools to diagnose and monitor the progres‑
sion of these diseases, and assessing the effectiveness of 
preventive and therapeutic strategies. Here, we provide 
an overview of the current state of knowledge regarding 
the role of α‑syn aggregation states in regulating α‑syn 
function under physiological and pathophysiological 
conditions. We also discuss the implications of these 
findings for therapeutic interventions.
Physiological function of α‑synuclein
Although the normal function (or functions) of α‑syn 
remains unknown, its localization at presynaptic termi‑
nals15–17 (FIG. 1a,b), its association with the distal reserve 
pool of synaptic vesicles18–20 and the deficiencies in syn‑
aptic transmissions observed in response to knockdown 
or overexpression of α‑syn suggest that α‑syn has a role 
in the regulation of neurotransmitter release, synaptic 
function and plasticity (FIG. 1c).
Snca‑knockout mice exhibit an impairment in hip‑
pocampal synaptic responses to prolonged trains of 
high‑frequency stimulation that deplete the docked and 
reserve pool of synaptic vesicles, as well as impairments 
in replenishment of docked pools from the reserve pool, 
indicating that α‑syn may control the refilling and the 
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Lewy body
An intraneuronal globular 
inclusion composed primarily 
of α‑synuclein fibrils. Lewy 
bodies are characteristically 
found in Parkinson’s disease, 
although they are also 
detectable in other 
neurodegenerative diseases, 
such as dementia with Lewy 
bodies.
Fibril
Mature fibrils are characterized 
by the following characteristics: 
a cross‑β‑sheet X‑ray fibre 
diffraction pattern; β‑sheet‑rich 
circular dichroism and Fourier 
transform infrared 
spectroscopy (FTIR) spectra; 
binding to Congo red and 
Thioflavin‑T/S; and a 
characteristic filamentous 
morphology (8–12 nm in 
diameter and >1 μm in length), 
as revealed by atomic force 
microscope and transmission 
election microscope imaging. 
α‑synuclein can form fibrils of 
diverse morphologies 
depending on the solution 
conditions.
trafficking of synaptic vesicles from the reserve pool to 
the site of synaptic vesicle release21,22. Moreover, depletion 
of α‑syn, through the use of antisense oligonucleotides, 
induces a decrease in the availability of reserve synaptic 
vesicle pool in primary cultured hippocampal neurons23.
Transgenic mice overexpressing human α‑syn exhibit 
impairment in synaptic vesicle exocytosis and a reduc‑
tion in neurotransmitter release24–26. Similar effects have 
been observed after α‑syn overexpression in genetic 
rodent models of PD27,28 and in the PC12 stable cell line29. 
At the ultrastructural level, overexpression of α‑syn 
induces a decrease in readily releasable vesicles27 and 
affects the recycling of synaptic vesicles following endo‑
cytosis, inducing a reduction in the size of the synaptic 
vesicle recycling pool26. Moreover, excess α‑syn induces 
a reduction in dopamine reuptake in dopaminergic ter‑
minals28 and inhibits intersynaptic trafficking of vesicles, 
leading to a smaller reserve pool of vesicles30.
The possible role of α‑syn in regulating synap‑
tic homeostasis is not exclusively related to its direct 
interaction with synaptic vesicles. α‑syn interacts with 
synaptic proteins controlling vesicle exocytosis, such as 
phospholipase D2 (REF. 31) and the family of RAB small 
GTPases32. Recent studies reported that α‑syn can act as 
Figure 1 | Functional properties of α‑synuclein. a,b | Wide field (a) and magnified (b) images of cultured cortical neurons 
from a postnatal day 1 wild‑type mouse. A neuronal dendrite (as revealed by MAP2 immunostaining; red) is shown 
opposed to α‑synuclein (α‑syn)‑positive presynaptic densities (green), indicating that α‑syn is located in presynaptic 
terminals. c | This schematic highlights the roles of α‑syn at the presynaptic terminal in the regulation of vesicle trafficking 
and vesicle refilling (α‑syn; blue), as well as the interactions between target membrane‑associated SNARE (t‑SNARE) and 
vesicle‑associated SNARE (v‑SNARE) proteins and neurotransmitter release. Accumulation of α‑syn induces an 
impairment of neurotransmitter release, vesicle recycling and trafficking between synaptic buttons and influences the 
stability of t‑SNARE complex assembly (α‑syn; red). Depletion of α‑syn induces an impairment of vesicle trafficking 
between the reserve pool and the ready releasable pool and a deficiency in vesicle refilling and neurotransmitter uptake 
(not shown).
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Oilgomer
Oligomers comprise a number 
of smaller, identical units 
(monomers). In the context of 
α‑synuclein oligomers, this 
term encompasses a wide 
range of species, ranging from 
low‑molecular‑weight species 
(including dimers, trimers and 
tetramers) to high‑molecular‑
weight species (such as 
spherical, chain‑like and 
annular structures.
a chaperone protein for the presynaptic SNARE protein 
complex by controlling the degradation and affecting the 
assembly, maintenance and distribution of this complex 
(FIG. 1c), which is directly implicated in the release of neu‑
rotransmitters, including dopamine33. Together, these 
observations indicate that α‑syn has an important role 
in the trafficking of synaptic vesicles and in the regula‑
tion of vesicle exocytosis, and may contribute to more 
subtle regulatory phenomena by controlling synaptic 
homeostasis‑associated proteins.
The fact that the individual synuclein knockouts (α‑, 
β‑ and γ‑syn) are viable suggests that synucleins are not 
essential components of the neurotransmitter release 
machinery but may contribute to the long‑term regulation 
and maintenance of nerve terminal function34. The neu‑
roprotective effects of α‑syn against progressive neurode‑
generation in mice deficient in cysteine‑string protein‑α 
(CSPα; also known as DNAJC5)35 strongly suggest that its 
functional properties become more prominent or essen‑
tial under conditions of stress. The neuroprotective func‑
tion of α‑syn appears to be mediated by its ability to bind 
to membranes and vesicles, as the A30P α‑syn mutant, 
which is deficient in membrane binding, failed to show 
protection in CSPα gene‑knockout mice.
Structure of α‑synuclein
Because a protein’s sequence and structure are linked 
to its function, a concerted effort has been made to 
characterize the sequence and structural determinants 
that govern the cellular properties of α‑syn and its aber‑
rant behaviour in PD and other synucleinopathies. 
α‑synuclein is a 14 kDa protein (140 amino acids; pKa of 
4.7)36 that is characterized by an amphipathic lysine‑rich 
amino terminus, which has a crucial role in modulat‑
ing its interactions with membranes, and a disordered, 
acidic carboxy‑terminal tail, which has been implicated 
in regulating its nuclear localization and interactions 
with metals, small molecules and proteins37,38 (FIG. 2a). 
The central region of α‑syn was first purified from 
amyloid plaques in patients with Alzheimer’s disease 
(AD)36,39. It contains a highly hydrophobic motif that 
comprises amino acid residues 65–90 and is known as 
the non‑amyloid‑β component of AD amyloid plaques 
(NAC)36,40,41 (FIG. 2a). The NAC region is indispensable for 
α‑syn aggregation; the deletion of large segments within 
this motif greatly diminished α‑syn oligomerization and 
fibrillogenesis in vitro42,43 and in a cell‑based assay44.
Studies by several groups using different bio‑
physical methods (for example, NMR, light scatter‑
ing and circular dichroism) consistently showed that 
α‑syn purified from Escherichia coli under native or 
denaturing conditions exists predominantly as stable 
unfolded monomers38,45. When α‑syn was extracted 
from patients diagnosed with LBD and age‑matched 
controls and evaluated by non‑denaturing gels or size 
exclusion chromatography (SEC) columns, α‑syn 
monomers migrated as 57–60 kDa proteins, but in 
denaturing gels they migrated as 14 kDa proteins42,44 
(FIG. 2b). Initially, the apparent size of α‑syn in native 
gels and SEC led many researchers to propose that 
this protein exists as a stable oligomer, but subsequent 
detailed biophysical studies demonstrated that the 
larger than expected size is mainly due to the fact that 
monomeric α‑syn adopts an unfolded, extended con‑
formation45,46, which results in a larger than expected 
hydrodynamic radius (BOX 1).
The apparently multifunctional properties of α‑syn 
may lie in its conformational flexibility, which may 
allow the protein to adopt different conformations upon 
interacting with biological membranes of different com‑
positions, other proteins or protein complexes47,48. It is 
well established that α‑syn adopts an α‑helical confor‑
mation upon binding to synthetic or biological mem‑
branes in vitro38. However, very little is known about the 
conformational state (or states) of α‑syn in the differ‑
ent compartments of the living cell, and there is a lack 
of direct evidence for a functional role of native α‑syn 
oligomers in biological membranes. It is conceivable 
that native α‑syn exists in equilibrium between differ‑
ent conformational and/or oligomeric states. Several 
factors, including oxidative stress49, post‑translational 
modifications50,51, proteolysis52,53 and the concentrations 
of fatty acids54–56, phospholipids and metal ions11,49, were 
shown to induce and/or modulate α‑syn structure and 
oligomerization in vitro, and these factors may influence 
this equilibrium between the monomer and oligomer 
state in vivo. Together, these studies suggest that α‑syn 
exists predominantly as a monomer, but do not rule out 
the possibility that it can form a stable multimer and/or 
adopt different structures under specific stress‑induced 
conditions or upon interaction with other proteins, 
specific ligands, lipids and/or biological membranes. 
Understanding the molecular determinants that regulate 
the conformational and oligomeric states of native α‑syn 
and the structural basis of its toxicity will be crucial for 
our ability to generate and test different mechanistic 
models and hypotheses of α‑syn function in health and 
disease. Gaining this knowledge will also have important 
implications for the development of therapeutic strate‑
gies based on targeting α‑syn, as discussed in the fol‑
lowing section.
α‑synuclein and disease
Paths to increased expression and accumulation of 
α‑synuclein. PD, DLB and other LBDs show accu‑
mulation and redistribution of α‑syn in various brain 
regions and cellular populations. These changes in the 
nature and localization of α‑syn may have pathogenic 
roles in these disorders (FIG. 2c) and can be reproduced 
in α‑syn transgenic animal models1,3,57–59 (FIG. 2d).
The levels of α‑syn in the CNS depend on the bal‑
ance between the rates of α‑syn synthesis, aggregation 
and clearance60 (FIG. 3a,b). An imbalance between these 
mechanisms, caused by dysfunction of one or more of 
these pathways, can result in abnormal levels of α‑syn 
that might favour the formation and/or accumulation 
of oligomeric and fibrillar species, which may be toxic. 
Indeed, in some familial forms of parkinsonism, mul‑
tiplication of SNCA results in increased accumulation 
α‑syn because of increased protein expression4, whereas 
in others, SNCA mutations enhance the propensity of 
α‑syn to aggregate9 (FIG. 3a). A genome‑wide association 
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study (GWAS) showed that individuals with certain vari‑
ations in the SNCA gene had a higher risk of PD61. One 
such polymorphism is known as Rep1, which occurs in 
the promoter region of SNCA and might increase the 
susceptibility to PD by increasing the expression of 
α‑syn62. Clearance of α‑syn monomers and aggregates 
occurs via direct proteolysis (for example, by neurosin 
or matrix metalloproteinase 9 (MMP9))63, binding to 
molecular chaperones (for example, heat shock proteins 
(HSPs))64, the proteasome65–67 and autophagy (involving 
the activity of the lysosome)60,68–70 (FIG. 3a). In sporadic 
forms of PD and DLB, failure of the autophagy pathways 
to eliminate oligomers might enhance α‑syn‑mediated 
toxicity69 (FIG. 3a). Chaperone‑mediated autophagy68 
has been shown to be disrupted by oligomeric forms of 
wild‑type and disease‑associated mutant α‑syn. In PD 
and DLB, the levels of key autophagy molecules such 
as ATG7, a ubiquitin‑like modifier‑activating enzyme, 
and mammalian target of rapamycin (mTOR), a serine/
threonine protein kinase, are dysregulated71.
Evidence for different conformers of α‑synuclein in dis‑
ease. There are a number of different α‑syn conform‑
ers, including oligomers, protofibrils and fibrils, that 
have been associated with the pathogenesis of LBDs. 
The fibrillar forms of α‑syn are detected mostly in Lewy 
bodies72,73, which are localized in the neuronal cell body. 
These intracellular structures are the neuropathologi‑
cal hallmark of PD and DLB (FIG. 2b) and are thought 
to reflect an attempt by the neurons to isolate and/or 
convert toxic α‑syn oligomers to fibrils, which are sta‑
ble, less dynamic structures that exhibit reduced toxicity. 
Aggregates of α‑syn can also be observed in astroglial 
cells from cases of LBD74. The distribution of α‑syn 
pathology in human diseases can be recapitulated in 
α‑syn transgenic mice75 (FIG. 2c).
Strong indirect evidence supports the existence of 
various oligomeric α‑syn species in vivo under patho‑
physiological conditions. SDS‑resistant dimers as well 
as low‑ and high‑molecular‑weight oligomeric forms of 
α‑syn have been detected in diseased human brains10,76,77 
and in brains of transgenic animal models of synucle‑
inopathies10,18,78 that express wild‑type or PD‑associated 
mutant variants of α‑syn79 (FIG. 2a). In contrast to fibrillar 
α‑syn, oligomeric aggregates are most likely to be located 
in axons (FIG. 1b) and presynaptic terminals, where they 
might damage synapses and dendrites25,26,28,80–82.
In vitro, several oligomeric species of different mor‑
phologies, including spherical, chain‑like and annular 
oligomers, have been observed before α‑syn fibril for‑
mation83 (FIG. 4). The various oligomeric species seem to 
exist in equilibrium with monomeric α‑syn and undergo 
a very slow conversion to fibrils in the absence of a high 
molar ratio of monomers to other species of α‑syn (FIG. 4). 
However, the relationships between the various α‑syn oli‑
gomeric species and mechanisms of the inter‑conversion 
between these different oligomers remain poorly under‑
stood, although some studies suggest that the formation 
of ring‑like oligomers is not on the pathway to amyloid 
formation. Of note, both in vitro and animal model stud‑
ies show that three PD‑linked SNCA mutations (A30P, 
E46K and A53T) accelerate α‑syn oligomerization, but 
only two of these (E46K and A53T) enhance fibrillization 
in vitro and in vivo9,42,84. Although the A30P mutation has 
been shown to result in enhanced α‑syn fibrillization 
in vivo, as illustrated by an autopsy case of a patient with 
this mutation who had extensive Lewy body pathology61, 
in vitro it exhibits reduced fibrillization compared with 
the wild‑type protein and other mutants.
Biophysical and SEC studies suggest that α‑syn SDS‑
resistant oligomers from post‑mortem human and 
transgenic animal brains can be in general divided into 
small (~2–5‑mers), medium (~5–15‑mers), and large 
(~15–150‑mers) oligomers85,86. Spherical oligomers 
2–6 nm in diameter may be the toxic forms of α‑syn, 
as they promote neuronal degeneration and abnormal 
calcium currents in cultured primary cortical neurons86.
Figure 2 | Biochemical structure of α‑synuclein and its pathological distribution in 
Parkinson’s disease, and a mouse model of Lewy body disease. a | Schematic 
representation of micelle‑bound α-synuclein (α-syn; Protein Data Bank ID: 1XQ8)37. 
The N-terminal region, the non-amyloid-β component of Alzheimer’s disease amyloid 
plaques (NAC) region and the C-terminal part are coloured blue, orange and red, 
respectively. Numbers refer to amino acid residues flanking the different regions.  
b | Western blot identifying α‑syn in brain homogenates from control and Lewy body 
disease (LBD) cases that were divided into cytosolic and particulate fractions. α‑syn 
migrated to 57–60 kDa as well as to 14 kDa in the particulate but not cytosolic fraction 
owing to the different conformational states of the protein. c,d | α‑syn is present in Lewy 
bodies, neurites, synapses and astroglia in dementia with Lewy bodies (DLB) and 
Parkinson’s disease (PD) and in transgenic (tg) mice overexpressing human wild‑type 
α‑syn (known as PDGFB–human wild‑type α‑syn mice), as indicated by arrows.
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It is important to stress that in almost all of the in vivo 
studies described in the literature, the detection of oli‑
gomeric forms of α‑syn was solely based on indirect 
evidence and the use of native and/or denaturing gel 
electrophoresis techniques46. Thus, it remains unknown 
to what extent the oligomers formed in vitro share simi‑
lar characteristics and size to those formed in vivo or 
isolated from human brains or brains of transgenic ani‑
mal models of synucleinopathies. Future studies would 
greatly benefit from tools that allow direct monitoring 
of protein oligomerization in living cells.
Toxicity of α‑synuclein oligomers and fibrils. Given the 
diversity and heterogeneity of the oligomers that form 
under different conditions and induce α‑syn aggregation 
and toxicity, it is likely that various α‑syn oligomeric spe‑
cies have a role in mediating α‑syn toxicity in neurons 
and, potentially, in glial cells.
Conversion of α‑syn to a toxic oligomeric form (or 
forms) might be influenced by interactions with lipids 
or small molecules and post‑translational modifica‑
tions, including phosphorylation87 of α‑syn at S129 and 
S87 (REF. 88), oxidative stress49,89 and truncation11. Under 
in vitro conditions, increasing protein concentrations, 
long incubations at 37 °C, addition of specific metal 
ions (Fe2+, Cu2+ and Zn2+)49,90, nitration89 or application 
of various ligands, such as dopamine91, can induce α‑syn 
self‑assembly (FIG. 3a) and the formation of variably sized 
soluble aggregates that are rich in β‑sheets. These range 
in stability and morphology, and some go on to form 
amyloid fibrils (FIG. 4).
Data collected in  vitro and in  vivo support the 
hypothesis that prefibrillar oligomers may represent the 
toxic species of α‑syn84,92. In vitro studies showed that 
annular protofibrils alter membrane permeability, result‑
ing in an increased influx of calcium from the extracel‑
lular to intracellular space that leads to cell death86. α‑syn 
oligomers might also cause toxicity by damaging mito‑
chondria93, triggering lysosomal leakage94 or disrupting 
microtubules95. Moreover, a recent study showed that 
α‑syn oligomers interfere with the axonal transport 
of synaptic proteins such as synapsin 1, resulting in 
dysfunctional synapses and eventual neurodegenera‑
tion25. It is likely that α‑syn toxicity occurs via different 
mechanisms and involves different intermediates on the 
pathway to fibril formation. However, recent evidence 
suggests that the process involving the conversion of 
oligomers to fibrils itself contributes to α‑syn toxicity 
and the progression of neurodegeneration. Mutations 
that promote fibrillization (such as S129A96,97) also 
enhance α‑syn‑induced toxicity and behavioural defi‑
cits in genetic rat models of PD, whereas mutations that 
Box 1 | The native state of α‑synuclein
The wide distribution and abundant expression of α‑synuclein (α‑syn) throughout the brain have been difficult to 
reconcile with its unfolded structure, which is expected to make the protein more susceptible to proteolysis and 
degradation. Thus, it was proposed that the oligomerization of α‑syn or its association with other proteins might 
represent mechanisms by which the protein may acquire different structures and functions in vivo. Two recent studies 
reported that native α‑syn exists as a folded tetramer126,127. The first study showed that α‑syn purified from mammalian 
cell lines or red blood cells exists as a stable α‑helical tetramer with an apparent size of 58–60 kDa, as was discerned by 
size exclusion chromatography (SEC), native PAGE (clear and blue‑native PAGE) and sedimentation equilibrium studies126. 
The second study used NMR, chemical crosslinking and SEC, and indicated that α‑syn produced in Escherichia coli exists 
as a ‘dynamic tetramer’ that is rich in α‑helical structure127. Both studies suggested that the tetrameric helical form of 
α‑syn is resistant to aggregation and fibril formation.
The above findings have not been verified independently. Indeed, studies from our own laboratories and three other 
independent groups showed that α‑syn produced in mammalian cell lines or red blood cells or isolated from the brain 
tissue of mice, rats, humans or α‑syn transgenic animals exhibited identical mobility in native and denaturing gels to the 
unfolded monomeric α‑syn produced in E. coli46. NMR data of α‑syn in intact cells also ruled out the presence of stable or 
highly populated α‑syn oligomers and confirmed the intrinsically disordered nature of the protein in E. coli regardless of 
its purification method128. N‑terminal acetylation, which was observed in native α‑syn isolated from cell lines and brain 
tissues, did not result in significant changes in the protein’s structure, oligomeric state, membrane‑binding properties or 
subcellular localization. These findings are in agreement with most studies on the oligomeric state of native α‑syn, which 
have consistently shown that α‑syn behaves as an unfolded monomer9,45,46. The migration of α‑syn with an apparent 
molecular weight slightly above 66 kDa in native gels and SEC is probably the result of its tendency to adopt extended 
conformations, and not because it exists in an oligomeric form (for example, as a tetramer), as the addition of denaturants 
or boiling of α‑syn samples from various sources did not change α‑syn migration128. Although Bartels et al.126 reported that 
chemical crosslinking of native α‑syn primarily stabilized α‑syn tetramers, studies by several groups, including the work 
by Wang et al.127, showed that chemical or photochemical crosslinking of α‑syn in mammalian cells or purified α‑syn from 
E. coli results in the formation of a ladder of α‑syn species ranging from monomers to hexamers, with dimers being the 
major species129, consistent with the pattern expected for nonspecific crosslinking. Interestingly, SDS‑resistant dimers 
seem to be the most commonly detected form of α‑syn oligomers in denaturing gels under conditions of oxidative 
stress49,130 or in the presence of specific metals and small molecules, such as polyphenols122. These dimers are stable in the 
presence of dissociative conditions such as reducing agents, chemical denaturants and boiling, suggesting that they are 
covalently crosslinked89,122.
The development of novel tools or methodologies that allow direct detection and monitoring of changes in α‑syn 
structure and oligomeric states in living cells and/or in vivo is required for assessing changes in the distribution of α‑syn 
conformations and oligomeric states in vivo and the role of these changes in regulating α‑syn normal function and 
toxicity. This knowledge is essential for the successful design of novel strategies for the diagnosis and treatment of 
Parkinson’s disease and related synucleinopathies.
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Figure 3 | Cellular events controlling intracellular α‑synuclein levels and possible therapeutic strategies to 
combat α‑synuclein accumulation and transmission. Intracellular α‑synuclein (α‑syn) levels are tightly regulated 
by the balance between the rates of α‑syn synthesis, clearance and aggregation. a | Abnormalities affecting α‑syn 
synthesis, including SNCA multiplication and polymorphisms (such as Rep1), may increase intracellular α‑syn levels 
and induce its accumulation. Accumulation may also be caused by a failure to degrade α‑syn. Clearance deficits 
might arise from failure of the ubiquitin–proteasome system, chaperone‑mediated autophagy dysfunction (induced 
by Parkinson’s disease‑linked mutations) or dysfunction of proteases (neurosin or matrix metalloproteinase 9 
(MMP9)). Finally, certain SNCA mutations, post‑translational modifications, oxidative stress, toxins and interaction 
with oxidized dopamine increase the propensity of α‑syn to aggregate and accumulate. b | Strategies to reduce 
α‑syn accumulation include decreasing α‑syn synthesis through use of small interfering RNA (siRNA) or microRNA 
(miRNA). Accumulation may also be decreased by activating mechanisms or proteins involved in clearance, such as 
autophagy, the proteasome, neurosin, MMP9 and heat shock proteins. Additionally, aggregation of α‑syn can be 
decreased using anti‑aggregating, antioxidant or post‑translational modification approaches, and immunotherapy 
may be used to block transmission and oligomer formation. Finally, various α‑syn‑independent neuroprotective 
strategies may also be used to protect neurons from α‑syn‑mediated toxicity.
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Figure 4 | Mechanisms of α‑synuclein aggregation and propagation. α‑synuclein (α‑syn) aggregation can take place 
either in the cytoplasm or in association with the cellular membrane. In the cytosol, unfolded monomers interact to form 
initially unstable dimers, which grow slowly to generate oligomers of varying morphologies — including transient 
spherical and ring‑like oligomers — that eventually convert to fibrils. The α‑syn oligomers are in equilibrium with 
monomers and convert to fibrils by monomer addition via a nucleated polymerization mechanism. The accumulation of 
these amyloid fibrils leads to the formation of intracellular inclusions called Lewy bodies. Membrane‑bound monomeric 
α‑syn adopts a predominantly α‑helical confirmation, but at high concentrations the protein undergoes a conformational 
change either before or coincident with its oligomerization to form membrane‑bound β‑sheet‑rich structures that 
self‑associate to form oligomers, including trans‑membrane amyloid pores (the formation of which may involve several 
intermediates)131 and fibrils. Note that the ring‑like cytosolic oligomers may also associate with the membrane and form 
trans‑membrane pores. During α‑syn fibrillogenesis and aggregation, the intermediate species (oligomers and amyloid 
fibrils) are highly toxic, affecting mitochondrial function, endoplasmic reticulum–Golgi trafficking, protein degradation 
and/or synaptic transmission, and these intracellular effects are thought to induce neurodegeneration. The 
transmembrane pores disrupt membrane integrity as well as intracellular calcium homeostasis and signalling, and may 
also contribute to neuronal toxicity. Interestingly, α‑syn oligomers and fibrils, as well as the monomers, can be transferred 
between cells and induce disease spreading to other brain regions. Spreading mechanisms are multiple and can occur via 
endocytosis, direct penetration, trans‑synaptic transmission or membrane receptors. Once inside the host cells, α‑syn 
aggregates can nucleate aggregation and propagate via the mechanisms described above.
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Box 2 | Key terminology in the field of prion‑like diseases
The term ‘transmission’ means the conveyance of non‑prion proteins, whereas the 
terms ‘propagation’, ‘spreading’, ‘transfer’ and ‘dissemination’ are used 
interchangeably to indicate the dispersal of protein over a larger area, as well as from 
cell to cell. ‘Seeding’ is synonymous with the addition of preformed aggregates to a 
solution of monomers. This process can eliminate the lag phase of aggregate growth 
that is associated with the formation of soluble assembly‑competent oligomers 
(known as the ‘nuclei’) and can accelerate fibril formation. Seeding is the theoretical 
basis for prion infectivity, or the conveyance of prion proteins from animal to animal.
Nuclei
Thermodynamically unstable 
oligomeric species that are 
capable of acting as sites for 
amyloid fibril growth.
Seed
A relatively stable entity (such 
as a fibril or fragmented fibril) 
that, when introduced into a 
solution containing monomeric 
subunits, serves as an effective 
nucleus and accelerates fibril 
formation (by eliminating the 
lag phase associated with 
nuclei formation) in a 
nucleation polymerization 
process.
block α‑syn oligomerization and fibrillogenesis (such as 
S87E) induce significantly less α‑syn aggregation, fibre 
pathology and dopaminergic loss in rat midbrains88. 
Artificial mutant variants of α‑syn (for example, E57K 
α‑syn) that enhance the formation of α‑syn oligomers 
but not fibrils were shown to be highly toxic to dopa‑
minergic neurons in different animal models of synucle‑
inopathies98. In addition, Taschenberger and colleagues 
showed that mutations that enhance α‑syn oligomeriza‑
tion (that is, A56P and the triple mutant A30P/A56P/
A76P) exhibit high toxicity, but sustained progressive 
loss of dopaminergic neurons was strongly dependent 
on the ability of the α‑syn variant to form fibrils in vivo12. 
These results are consistent with recent findings in the 
amyloid‑β field99,100 and demonstrate that the process of 
fibril formation, rather than the fibrils themselves, has 
an important role in α‑syn toxicity and progressive neu‑
rodegeneration in PD and related disorders. Thus, it is 
possible that toxicity might be related to the process of 
aggregation rather than just to the final outcome (that is, 
oligomers or fibrils).
Although most of the studies mentioned here suggest 
that α‑syn oligomerization and/or fibrillogenesis has 
a central role in α‑syn toxicity, it is important to stress 
that most of the evidence demonstrating comparatively 
reduced toxicity for monomeric α‑syn is based on the use 
of recombinant proteins in extracellular toxicity assays or 
on the correlation between high levels of α‑syn oligom‑
ers (as determined by SDS–PAGE) and the progression 
of neurodegeneration in transgenic animals and other 
experimental models.
Of note, none of the available data excludes the two 
other possibilities, the first of which is that α‑syn oli‑
gomerization within specific cellular compartments may 
alter the distribution of functional forms of monomeric 
α‑syn or result in monomer sequestration into non‑
functional oligomeric forms, thus resulting in partial loss 
of α‑syn function101. The second possibility is that the 
native or misfolded forms of the monomeric protein may 
also contribute to α‑syn toxicity and PD pathogenesis via 
aggregation‑independent mechanisms, including aber‑
rant interactions with membranes, proteins and small 
molecules, retention in specific cellular compartments, 
and disruption of specific cellular processes. Unlike 
stable oligomeric forms of α‑syn, which can be easily 
distinguished from monomers and fibrils, the existing 
experimental tools do not allow the detection and char‑
acterization of different α‑syn monomeric conformers 
and thus preclude studies aimed at investigating the 
role of the α‑syn monomer in health and disease.
Propagation and transmission of α‑synuclein in the 
pathogenesis of PD. Under physiological conditions, 
α‑syn has been traditionally considered to be an 
exclusively intracellular synaptic protein that asso‑
ciates with vesicles15. However, recent evidence sug‑
gests that under pathological circumstances, toxic 
α‑syn oligomers could be eliminated from neurons 
via unusual secretory mechanisms102–104 (FIG.  4). 
Failure of the intracellular clearance pathways, such 
as autophagy, might contribute to the pathological 
release of α‑syn105. Pathways leading to the release 
of toxic α‑syn oligomers include exocytosis in clear 
vesicles105, exosomal release103,106 and penetration79,107 
from the donor cell membrane (FIG. 4). Interestingly, 
these extracellular α‑syn aggregates can then transfer 
from neuron to neuron or from neuron to glial cell105, 
where they can nucleate further intracellular aggrega‑
tion and/or trigger neuro‑inflammation to exacerbate 
the neurodegenerative process69,108. Supporting the 
potential relevance of this process in the pathogen‑
esis of α‑synucleinopathies, previous studies have 
shown accumulation of α‑syn in fetal grafted neurons 
in patients with PD109,110, as well as in grafted neu‑
ronal precursor cells in the hippocampus69 and basal 
ganglia111 in mouse models. Interestingly, α‑syn has 
also been shown to ectopically accumulate in oligo‑
dendroglial cells in multiple system atrophy (another 
synucleinopathy)112 and in astroglial cells in PD113,114. 
Moreover, the ascending distribution of the Lewy body 
pathology in LBD, as described by Braak113, has been 
interpreted to support the dissemination of α‑syn from 
subcortical to cortical brain regions. However, further 
in vivo experimental verification of this is needed. A 
definition for the terms of propagation, dissemination 
and infectivity is provided in BOX 2.
The mechanisms through which extracellular α‑syn 
oligomers transfer to other cells include endocytosis115, 
direct penetration116, trans‑synaptic dissemination103 and 
membrane‑receptor‑mediated access105. Once inside the 
acceptor cell, α‑syn oligomers could act as a focal point 
for further intracellular aggregation or the protein could 
be targeted for degradation. Although the exact process 
of intracellular oligomer and fibril propagation remains 
unknown, evidence from in vitro biophysical studies has 
consistently shown that fibrillization of α‑syn follows a 
nucleated polymerization mechanism92. This mecha‑
nism is characterized by a nucleation phase that initially 
involves the formation of assembly‑competent oligom‑
ers (nuclei), which is followed by cooperative oligomer 
growth and fibril formation by monomer addition117 
(FIG. 4). This process can be seeded (initiated) and accel‑
erated by the addition of preformed fibrils (the seed) and 
is thought to serve as the underlying mechanism for the 
spreading of α‑syn pathology in the brain. This phenom‑
enon has been observed in a cell‑based assay in which 
the introduction of recombinant α‑syn fibrils results in 
seeding, the recruitment of endogenous α‑syn and the 
formation of Lewy body‑like inclusions44. A recent in vivo 
study has shown that inoculation of α‑syn transgenic 
mice with homogenates containing α‑syn protofibrils 
and fibrils results in considerable enhancement of the 
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α‑syn pathology and propagation118. These observations 
have led to the provocative hypothesis that extracellu‑
lar α‑syn seeds might behave in a prion‑like fashion. 
Further experimental evidence is needed to confirm 
this hypothesis.
Perspectives on therapeutic targets
Given the potential toxicity of various α‑syn aggregates, 
therapeutic approaches for synucleinopathies might 
involve reducing the levels or accumulation of intra‑
cellular and extracellular α‑syn. One way to reduce the 
accumulation of intracellular α‑syn may be to reduce 
the expression of this protein by silencing SNCA 
with microRNA or by repressing the SNCA promoter 
(FIG. 3b). Another approach could involve clearing α‑syn 
by activating autophagy or the proteasome, by increas‑
ing proteolytic breakdown of α‑syn with cathepsin D, 
neurosin or MMP9, or by promoting the binding of 
α‑syn to chaperone‑like molecules such as β‑syn and 
HSPs (FIG. 3b). A third approach would be to reduce 
the post‑translational modifications, such as oxida‑
tion, nitration, phosphorylation and C‑terminal cleav‑
age (FIG. 3b). Two other possibilities may be to reduce 
aggregation or stabilize the native state of α‑syn (FIG. 3b).
Resolving the question of whether α‑syn exists as a 
monomer or as an oligomer under physiological and 
pathophysiological conditions is important not only in 
defining the function of this molecule but also in terms of 
developing therapeutic approaches for synucleinopathies. 
For example, if native α‑syn exists as a multimer, which 
has not yet been proven, then one therapeutic strategy 
for PD and DLB could involve preventing this complex 
from breaking apart. However, if toxic α‑syn oligomers 
are derived from single conformers, viable therapeutic 
approaches might include the stabilization of monomers, 
the stabilization of non‑propagating α‑syn dimers, the 
inhibition of α‑syn oligomerization and the prevention 
of interactions between monomers and protofibrils that 
result in fibril growth. As in vitro studies of multiple amy‑
loidogenic proteins119 have shown that fibril growth and 
disassembly occur via monomer addition to protofibrils 
and disassociation, respectively, α‑syn toxicity would be 
dependent not only on the levels of oligomers but also 
on the concentration of the monomers. The main issue 
relating to developing small molecules to stabilize mono‑
meric α‑syn or prevent the formation of toxic forms of 
α‑syn is that the monomer lacks a well‑defined structure 
or hydrophobic pockets. Additionally, the identity and 
three‑dimensional structure of toxic oligomeric species 
and their mode of action remain the subject of active 
investigation and debate.
If oligomeric α‑syn species are the primary cause of 
toxicity in synucleinopathies, then inhibition of α‑syn 
oligomerization or enhancement of α‑syn fibrillization 
should attenuate α‑syn toxicity and prevent neurodegen‑
eration. Conversely, small molecules and/or mutations 
that stabilize toxic α‑syn oligomers should enhance neu‑
rodegeneration. Interestingly, the large majority of mole‑
cules that inhibit α‑syn fibrillization exert their effects by 
stabilizing high‑molecular‑weight oligomeric intermedi‑
ates on the amyloid pathway120 and protect, rather than 
enhance, α‑syn toxicity121. This protective effect might 
be related to the antioxidant and anti‑inflammatory 
properties of some of these compounds, such as poly‑
phenols and curcuminoids122. Alternatively, it is possible 
that the binding of these molecules to oligomeric spe‑
cies of α‑syn blocks interactions between α‑syn and key 
mediators of α‑syn‑associated toxicity. Interestingly, this 
seems to be the case for most amyloid‑β inhibitors as 
well123: the majority of the compounds shown to protect 
against amyloid‑β toxicity do not stabilize monomeric 
amyloid‑β and promote the accumulation of oligom‑
ers and/or non‑fibrillar aggregates of various sizes and 
morphologies. It is possible that these molecules induce 
remodelling of the toxic oligomers and/or promote the 
formation of non‑toxic aggregate or pathways. A recent 
study by Ayrolles‑Torro et al.124 showed that small mol‑
ecule inhibitors that stabilize oligomeric forms of the 
prion protein attenuate prion infectivity in vivo, again 
suggesting a direct link between the processes of oli‑
gomer growth, fibrillization and prion infectivity.
The levels of toxic extracellular α‑syn aggregates 
may be reduced by targeting them with specific 
antibodies (passive and active immunotherapy), by 
increasing clearance, by blocking putative receptors for 
extracellular α‑syn in acceptor cells, by reducing α‑syn 
endocytosis and exocytosis or by targeting exosomes. 
Moreover, given the pro‑inflammatory effects of α‑syn, 
reducing microglial or astroglial activation with non‑
steroidal anti‑inflammatory drugs may also be a fruitful 
area of research125. Currently, the most viable therapeu‑
tic strategies for PD, DLB and related disorders may be 
to use the considerable biophysical and structural data 
available for the single conformation of α‑syn to target 
α‑syn monomers and decrease their synthesis, increase 
their clearance, block their interactions with oligomers 
or promote their stabilization. Ultimately, developing 
a successful therapy for synucleinopathies will require 
multidisciplinary research combined with multimodal 
therapeutics.
Conclusions
Since the discovery of α‑syn in the mammalian brain, 
research has focused on better understanding the con‑
tributions of this natively unfolded protein to vesicular 
synaptic function under normal conditions. The dis‑
covery of disease‑linked mutations and multiplications 
in SNCA that cause familial PD and accelerate α‑syn 
oligomerization in vitro has resulted in greater emphasis 
on elucidating the role of α‑syn oligomers and fibrils as 
well as prion‑like α‑syn propagation in the pathogenesis 
of LBDs. Therapeutic interventions directed at reducing 
α‑syn synthesis, toxicity and aggregation or at increas‑
ing α‑syn clearance are currently being investigated in 
preclinical models and hold promise for developing 
future treatments for α‑synucleinopathies. We believe 
that more emphasis on elucidating the molecular and 
structural bases of the suspected physiological func‑
tions of α‑syn is needed. This may help us to further 
understand the functions of this protein and provide 
novel molecular targets for therapeutic intervention in 
α‑syn‑linked diseases.
Native state
The three‑dimensional 
structure of the protein in its 
normal physiological milieu in 
the absence of any denaturing 
agents or conditions.
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